Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738291 | 1.00 | MDM4 (0.47) | MDM4TP53CASP3PTPN1MDM2 | |
| SCHEMBL29401054 | 0.89 | PTPN1 (0.46) | MDM4TP53PTPN1MDM2 | |
| SCHEMBL1739184 | 0.89 | PTPN1 (0.46) | MDM4TP53PTPN1MDM2 | |
| SCHEMBL9732777 | 0.88 | PTPN1 (0.51) | MDM4TP53CASP3PTPN1MDM2 | |
| SCHEMBL2066552 | 0.88 | MDM4 (0.47) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL14725461 | 0.87 | CASP3 (0.45) | MDM4TP53CASP3MDM2KMT2A | |
| SCHEMBL2977877 | 0.87 | ATM (0.53) | MDM4TP53CASP3TNF | |
| SCHEMBL13743302 | 0.87 | ATM (0.53) | MDM4TP53CASP3TNF | |
| SCHEMBL12531899 | 0.87 | ATM (0.53) | MDM4TP53CASP3TNF | |
| SCHEMBL29401932 | 0.87 | ATM (0.53) | MDM4TP53CASP3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-1984928-A | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | AVANIR PHARMACEUTICALS (US) | 2007-06-20 | — | — | CN | disclosed |
| EP-1753782-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| WO-2005123770-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | MDM4 4496/4885TP53 4543/4885CASP3 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.